A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening

Journal of Thoracic Oncology

Volumn 7, Issue 4, 2012, Pages 698-708

  Bigbee, William L ^a,b   Gopalakrishnan, Vanathi ^b,c   Weissfeld, Joel L ^a,b   Wilson, David O ^c   Dacic, Sanja ^b   Lokshin, Anna E ^a,b   Siegfried, Jill M ^a,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b Public Health   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

CT screening; Luminex xMAP immunoassays; Lung cancer; Pulmonary nodules; Serum protein biomarkers

Indexed keywords

BIOLOGICAL MARKER; CC MOTIF CHEMOKINE 5; CYTOKERATIN FRAGMENT 21.1; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; MACROPHAGE MIGRATION INHIBITION FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR; PREALBUMIN; PROLACTIN; PROTEIN ERBBETA 2; RECEPTOR TYROSINE PROTEIN KINASE; SERUM AMYLOID A; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER SCREENING; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RESPIRATORY TRACT DISEASE; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

EID: 84858766991     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31824ab6b0     Document Type: Article

References (50)

1. Goodwin PJ, Shepherd FA. Economic issues in lung cancer: a review. J Clin Oncol 1998;16:3900-3912. (Pubitemid 29001544)
2. Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. CA Cancer J Clin 2007;57:90-104. (Pubitemid 46535709)
3. Kaneko M, Eguchi K, Ohmatsu H, et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 1996;201:798-802.
4. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999;354:99-105. (Pubitemid 29313143)
5. Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 2000;92:1308-1316. (Pubitemid 30660590)
6. Welch HG, Woloshin S, Schwartz LM, et al. Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med 2007;167:2289-2295. (Pubitemid 350179522)
7. Wilson DO, Weissfeld JL, Fuhrman CR, et al. The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan. Am J Respir Crit Care Med 2008;178:956-961.
8. Croswell JM, Baker SG, Marcus PM, Clapp JD, Kramer BS. Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med 2010;152:505-512, W176.
9. The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. New Engl J Med 2011;365:395-409.
10. Okada M, Nishio W, Sakamoto T, et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg 2005;129:87-93. (Pubitemid 40038100)
11. Buccheri G, Torchio P, Ferrigno D. Clinical equivalence of two cytokeratin markers in mon-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments. Chest 2003;124:622-632. (Pubitemid 37000143)
12. Pastor A, Menéndez R, Cremades MJ, Pastor V, Llopis R, Aznar J. Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis. Eur Respir J 1997;10:603-609. (Pubitemid 27112576)
13. Wilson DO, Weissfeld JL, Balkan A, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med 2008;178:738-744.
14. Zeh HJ, Winikoff S, Landsittel DP, et al. Multianalyte profiling of serum cytokines for detection of pancreatic cancer. Cancer Biomark 2005;1:259-269.
15. Yurkovetsky Z, Skates S, Lomakin A, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010;28:2159-2166.
16. Gorelik E, Landsittel DP, Marrangoni AM, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:981-987. (Pubitemid 40478567)
17. Arslan AA, Gu Y, Zeleniuch-Jacquotte A, et al. Reproducibility of serum pituitary hormones in women. Cancer Epidemiol Biomarkers Prev 2008;17:1880-1883.
18. Gu Y, Zeleniuch-Jacquotte A, Linkov F, et al. Reproducibility of serum cytokines and growth factors. Cytokine 2009;45:44-49.
19. Linkov F, Gu Y, Arslan AA, et al. Reliability of tumor markers, chemokines, and metastasis-related molecules in serum. Eur Cytokine Netw 2009;20:21-26.
20. Clearwater SH, Provost FJ. RL4: A tool for knowledge-based induction. In Proceedings of the Second International IEEE Conference on Tools for Artificial Intelligence (TAI-90), Herndon, VA, 1990.
21. Hennessy D, Gopalakrishnan V, Buchanan BG, et al. Induction of rules for biological macromolecule crystallization. In Proceedings of Second International Conference on Intelligent Systems for Molecular Biology, AAAI Press, Stanford, CA, 1994.
22. Lee Y, Buchanan BG, Aronis JM. Knowledge-based learning in exploratory science: learning rules to predict rodent carcinogenicity. Mach Learn 1998;30:217-240.
23. Gopalakrishnan V, Livingston G, Hennessy D, Buchanan B, Rosenberg JM. Machine-learning techniques for macromolecular crystallization data. Acta Crystallogr D Biol Crystallogr 2004;60(Pt 10):1705-1716. (Pubitemid 41079691)
24. Ranganathan S, Williams E, Ganchev P, et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 2005;95:1461-1471. (Pubitemid 41779269)
25. Gopalakrishnan V, Ganchev P, Ranganathan S, et al. Rule learning for disease-specific biomarker discovery from clinical proteomic mass spectra. Springer Lect Notes Comput Sci 2006;3916:93-105. (Pubitemid 44021368)
26. Ryberg H, An J, Darko S, et al. Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve 2010;42:104-111.
27. Holdenrieder S, von Pawel J, Dankelmann E, et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res 2008;14:7813-7821.
28. Kamimura A, Kamachi M, Nishihira J, et al. Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer 2000;89:334-341. (Pubitemid 30489881)
29. Tomiyasu M, Yoshino I, Suemitsu R, Okamoto T, Sugimachi K. Quantification of macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance. Clin Cancer Res 2002;8:3755-3760. (Pubitemid 35424766)
30. Bhatavdekar JM, Patel DD, Chikhlikar PR, et al. Levels of circulating peptide and steroid hormones in men with lung cancer. Neoplasma 1994;41:101-103. (Pubitemid 24142136)
31. Recchione C, Galante E, Secreto G, Cavalleri A, Dati V. Abnormal serum hormone levels in lung cancer. Tumori 1983;69:293-298.
32. Yildiz PB, Shyr Y, Rahman JS, et al. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol 2007;2:893-901. (Pubitemid 47511591)
33. Gogali A, Charalabopoulos K, Zampira I, et al. Soluble adhesion molecules E-cadherin, intercellular adhesion molecule-1, and E-selectin as lung cancer biomarkers. Chest 2010;138:1173-1179.
34. Guney N, Soydinc HO, Derin D, et al. Serum levels of intercellular adhesion molecule ICAM-1 and E-selectin in advanced stage non-small cell lung cancer. Med Oncol 2008;25:194-200.
35. Roselli M, Mineo TC, Martini F, et al. Soluble selectin levels in patients with lung cancer. Int J Biol Markers 2002;17:56-62. (Pubitemid 34308477)
36. Swellam M, Ragab HM, Abdalla NA, El-Asmar AB. Soluble cytokeratin-19 and E-selectin biomarkers: their relevance for lung cancer detection when tested independently or in combinations. Cancer Biomark 2008;4:43-54. (Pubitemid 351343911)
37. Abdel Salam I, Gaballa HE, Abdel Wahab N. Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation. Med Oncol 2009;26:161-166.
38. Filiberti R, Marroni P, Paganuzzi M, et al. c-erbB-2 protein in serum of primary lung cancer patients. Cancer Detect Prev 2002;26:64-68. (Pubitemid 36087184)
39. Jacot W, Pujol JL, Boher JM, Lamy PJ. Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer. Br J Cancer 2004;91:430-433. (Pubitemid 39093559)
40. Molina R, Jo J, Filella X, et al. Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumour Biol 1997;18:188-196. (Pubitemid 27204765)
41. Dudek AZ Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 2005;23:193-200. (Pubitemid 40770736)
42. Liu L, Liu J, Dai S, et al. Reduced transthyretin expression in sera of lung cancer. Cancer Sci 2007;98:1617-1624. (Pubitemid 47308460)
43. Khan N, Cromer CJ, Campa M, Patz EF Jr. Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma. Cancer 2004;101:379-384. (Pubitemid 38890843)
44. Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE 2nd. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 2007;25:5578-5583.
45. Yee J, Sadar MD, Sin DD, et al. Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol 2009;27:2787-2792.
46. Patel K, Farlow EC, Kim AW, et al. Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers. Int J Cancer 2011;129:133-142.
47. Pine SR, Mechanic LE, Enewold L, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst 2011;103:1112-1122.
48. Taguchi A, Politi K, Pitteri SJ, et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 2011;20:289-299.
49. Qiu J, Choi G, Li L, et al. Occurrence of autoantibodies to annexin I, 14-3-3 Theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 2008;26:5060-5066.
50. Wu L, Chang W, Zhao J, et al. Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer. Clin Cancer Res 2010;16:3760-3768.